Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan Plus Cisplatin As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix

NCT00136955 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00136955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00136955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan Plus Cisplatin As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2004
Completion date
May 31, 2008
Enrollment
41 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

uterine cervical neoplasms